Madrigal Pharmaceuticals, Inc.

Pharmaceutical Preparations

MDGLStrong5 of 9 basics passed

$471.75

-1.08%

Market cap $10.9B

$471.75

-1.08%

Market cap $10.9B

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature…

It is a $10.9B healthcare company. Revenue grew 149.0% over the last year, it currently loses money, and it holds more cash than debt.

Website: madrigalpharma.com
Location: West Conshohocken, PA
Employees: 915
Sector: Healthcare

Share price · 3 years

$149.41 → $471.75+215.7%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $1.28B
Loss: spends more than it earns; -$325M
Free cash flow: cash left after running the business; -$207M
Net cash: more cash than debt; $644M
Shares: up 31% since 2021 — dilution; 22.4M

Revenue, last 5 years

52-week range

Low $412.35$471.75High $602.83

Today's price is 31% of the way from the year's low to its high.

Valuation vs own history

P/S

8.5×

100%

P/B

20.8×

36%

Share of the last ~5 years that was pricier than today (cheaper than usual). Based on the daily valuation record.

Insider activity · 90 days

-$3.78Mnet selling

Purchases$0

Sales$3.78M

Insiders trading, last 14d0 buy · 0 sell

Standing in Healthcare

Size$10.9Btop 81%
Net margin-25%top 84%
Return on equity-57%top 92%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Strong health; Valuation, Growth, Profitability, Quality and Moat lag behind.

Valuation22

P/E vs own historyn/a · 10/25
FCF yield-1.9% · 0/25
P/S8.5x · 12/25
EV/EBITDA660.7x · 0/25

Growth0

Revenue CAGRn/a · 0/25
Net income CAGRn/a · 0/25
EPS CAGR ~5Yn/a · 0/25
Fwd implied growthn/a · 0/25

Profitability0

ROICn/a · 0/25
ROE-56.6% · 0/25
Net margin-25.3% · 0/25
Operating margin-25.3% · 0/25

Health75

Altman Z7.49 · 25/25
Current ratio3.20 · 25/25
Interest coverage-163.1x · 0/25
Net cash / debtNet cash · 25/25

Quality5

Piotroski F3/9 · 5/25
Beneish M0.14 · 0/25
FCF conversionn/a · 0/25
Margin stabilityσ 656.5% · 0/25

Moat0

ROIC >12% yearsn/a · 0/25
Median gross marginn/a · 0/25
FCF-positive years0/10 yrs · 0/25
Worst-year net marginn/a · 0/25

How the scores work →

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$55 697 today — price return only

$958.4M revenue in FY2025

Revenue up 149.0% year over year

915 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

High gross margin (91.5%)
Revenue growing 149.0% year over year
Net cash position after subtracting debt from cash
Altman Z-Score 7.49 — low bankruptcy-risk zone

Watch-outs

Not profitable — 25.3% net margin
Negative free cash flow (-$207.1M)
Thin interest coverage (-163.1×)
Loss-making in 10 of the recent years

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

5 of 9 checks passed

Revenue growing — the company sells more than a year ago+149.0% YoY
Profitable — makes more than it spends-$325M TTM
Profit growing — earnings are higher than last year+38.1% YoY
Generates cash — cash left after running and investing-$207M TTM
Debt under control — could handle its obligationsmore cash than debt
Established company — not a micro-cap — lower blow-up risk$10.9B market cap
Not printing shares — share count not ballooning — you keep your slice+31.2% shares over ~5y
Proven track record — years of profitability behind it0/10 profitable years
Financially stable — balance sheet not near distressAltman Z 7.5 — safe
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsno data

Peer comparisonMadrigal Pharmaceuticals, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
MDGL this company	$10.9B	—	+149.0%	-25.3%	Strong
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: MDGL vs LLY · MDGL vs JNJ · MDGL vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 6Buy 16Hold 2

Appendix · Financial records

The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $1.28B · net income -$325M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$1.28B

YoY 149.0%

Net income (TTM)

-$325M

Margin -25.3%

Gross margin

91.5%

Operating margin

-25.3%

Income statement — full detail

Figures in USD billions · EPS in USD

	2020	2021	2022	2023	2024	2025
Revenue	0.0	0.0	—	0.0	0.2	1.0
Gross profit	—	—	—	—	0.2	0.9
Operating income (EBIT)	-0.2	-0.2	-0.3	-0.4	-0.5	-0.3
Net income	-0.2	-0.2	-0.3	-0.4	-0.5	-0.3
EPS (diluted)	—	-14.14	-17.24	-19.99	-21.90	-12.85

Cash flowFree cash flow -$207M · operating cash flow -$198M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

-$207M

Margin -16.1%

Operating cash flow (TTM)

-$198M

FCF margin

-16.1%

Cash flow statement — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Operating cash flow	-0.2	-0.2	-0.2	-0.3	-0.5	-0.2
Capital expenditure	-0.0	-0.0	-0.0	-0.0	-0.0	-0.0
Free cash flow	-0.2	-0.2	-0.2	-0.3	-0.5	-0.2
FCF margin	—	—	—	—	-253.7%	-19.8%

Balance sheetAssets $1.26B · net cash $644M (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $1.26B of assets is financed

52%

48%

Liabilities $657M — borrowed moneyEquity $603M — owners' stake

Cash vs debt

Total debt $340M − cash $984M = net cash $644M

Cash on hand covers all debt.

Altman Z-Score

7.49

Safe zone

Debt repayment

Not needed

Cash already covers all debt

Interest coverage

-163.1x

EBIT ÷ interest expense

ROE

-56.6%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Cash & equivalents	0.3	0.3	0.4	0.6	0.9	1.0
Total assets	0.3	0.3	0.4	0.6	1.0	1.3
Total liabilities	0.0	0.1	0.2	0.2	0.3	0.7
Total debt	0.0	0.0	0.0	0.1	0.1	0.3
Equity	0.2	0.2	0.2	0.4	0.8	0.6
Net debt	-0.3	-0.3	-0.3	-0.5	-0.8	-0.6

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of MDGL on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $471.75 · market cap $10.9B.